Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8550655 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2MMP8GAAPIN1MEN1 | |
| SCHEMBL23027213 | 0.86 | POLB (0.54) | SMN1; SMN2MMP8GAAPIN1TDP1 | |
| SCHEMBL7038420 | 0.86 | POLB (0.54) | SMN1; SMN2MMP8GAAPIN1TDP1 | |
| SCHEMBL27846661 | 0.85 | KMT2A (0.55) | SMN1; SMN2MEN1KMT2ATSHRMAPT | |
| SCHEMBL6671021 | 0.85 | MMP8 (0.51) | SMN1; SMN2MMP8GAAPIN1TDP1 | |
| SCHEMBL4206097 | 0.83 | MMP8 (0.50) | SMN1; SMN2MMP8GAAPIN1TDP1 | |
| SCHEMBL10587417 | 0.83 | MMP8 (0.50) | SMN1; SMN2MMP8GAAPIN1TDP1 | |
| SCHEMBL8564225 | 0.83 | GAA (0.52) | SMN1; SMN2MMP8GAAPIN1TDP1 | |
| SCHEMBL28470487 | 0.83 | MMP8 (0.50) | SMN1; SMN2MMP8GAAPIN1TDP1 | |
| SCHEMBL8912905 | 0.83 | MMP8 (0.53) | SMN1; SMN2MMP8GAAPIN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020007071-A1 | Benzimidzolyl neuropeptide Y receptor antagonists | BRITTON THOMAS CHARLES (US) | 2002-01-17 | — | — | US | disclosed |
| US-6255494-B1 | SUBSTITUTED BENZIMIDAZOLES USEFUL IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH EXCESS OF NEUROPEPTIDE Y (AROUND ARTERIES IN HEART, RESPIRATORY TRACT, GASTROINTESTINAL TRACT AND GENITOURINARY TRACT); ETIOLOGY OF PSYCHIATRIC DISORDERS | ELI LILLY AND COMPANY | 2001-07-03 | — | — | US | disclosed |
| EP-0871442-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0506478-B1 | Piperidine derivatives | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1997025041-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5250542-A | Prevention of side effects induced by narcotics used as analgesics such as constipation, nausea and vomiting; 1-carboxyalkyl-4-methyl-4-(3-oxyphenyl)piperidines such as alvimopan | ELI LILLY AND COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0506478-A1 | Piperidine derivatives | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007071-A1 | Benzimidzolyl neuropeptide Y receptor antagonists | NPY1R, NPY2R, NPY5R | SMN1; SMN2 2698/4885MMP8 2207/4885GAA 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.